## ADMA: ADMA Biologics, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.34 indicates fundamental undervaluation. Quality metrics strong (ROE 63%, ROA 22%). Caution: momentum weakening (-2.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($18.07)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Assessing ADMA Biologics (ADMA) Valuation After Its Upgraded 2025 Revenue Guidance**
- Source: Sahm | 20251223T080904 | Bullish | Relevance: 100%
- ADMA Biologics recently raised its 2025 revenue guidance to $510 million, indicating strong growth momentum with a 14% one-month share price return and over 430% total shareholder return in three years. Despite significant past gains, the company is considered approximately 28.1% undervalued with a narrative fair value of $27.25, supported by long-term growth prospects, improved liquidity from debt refinancing, and potential for enhanced free cash flow and EPS. However, its valuation depends on successfully scaling its yield enhancement process and navigating competition and regulation within its specialized IVIG portfolio.

**2. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance**
- Source: Insider Monkey | 20251221T140937 | Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income to $158 million due to a higher effective tax rate. ADMA Biologics specializes in developing and marketing plasma-derived biologics for immune deficiencies and infectious diseases.

**3. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance**
- Source: Finviz | 20251221T085400 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also made a modest adjustment to its 2025 adjusted net income, now projected at $158 million, due to a higher effective tax rate. ADMA Biologics is a biopharmaceutical company focused on developing, manufacturing, and marketing plasma-derived biologics for immune deficiencies and infectious diseases.

**4. Texas Permanent School Fund Corp Has $1.87 Million Holdings in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251222T100931 | Bullish | Relevance: 100%
- The Texas Permanent School Fund Corp recently decreased its stake in ADMA Biologics Inc. by 39.3%, now holding 102,932 shares valued at approximately $1.87 million. Despite this, other major institutions significantly increased their positions, raising institutional ownership to 75.68%. Analysts maintain a "Buy" rating for ADMA, with a consensus price target of $28.50, following the company's meeting of EPS estimates and a 12% year-over-year revenue increase in its latest quarter.

**5. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance**
- Source: Yahoo Finance | 20251221T140937 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance, projecting total revenue of $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income modestly to $158 million due to a higher effective tax rate. ADMA Biologics specializes in plasma-derived biologics for immune deficiencies and infectious diseases.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.08M) |
| Sells | 2 ($0.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.2% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.6%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.34 suggests fair value with growth premium. Forward P/E 20.7x attractive for 57% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.43 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.34 |
| Forward P/E | 20.7 |
| Current P/E | 32.5 |
| YoY Growth | 56.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 1.0% to -1.2% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 58. OFD pattern: -F0L (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.20% (CS: 41) | Neutral |
| RSI_14 | 58.2 | Neutral |
| MACD Histogram | -0.16 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.142x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $19.49
- **Stop Loss:** $18.07 (7.3% risk)
- **Target:** $22.33 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 845
- **Position Value:** $16,469.05
- **Portfolio %:** 16.47%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*